| 영문 | radiation dose | 한글 | 방사선량 |
|---|---|---|---|
| 설명 | 방사선조사의 정도. 방사선생물학이나 인체의 방사선방호에서는 전리방사선의 양, 즉 선량이 문제가 된다. 방사선량에서도 국제단위계(SI)가 채용되어 국제방사선방호위원회(ICRP)의 권고에 따라서 다음의 여러 단위가 널리 사용된다. ① 흡수선량(absorbed dose). 물질의 단위질량이 방사선에 의해 받아들이는 에너지. 이 단위는 방사선 및 물질의 종류가 어떠한 것이더라도 사용할 수 있다. 국제단위는 J/kg이며 이것에 고유한 명칭으로 그레이(gray, 기호 Gy)가 부여된다. 1Gy=100라드(rad). ② 조사선량(exposure) 또는 공중선량. X선 또는 γ선에 한해서 사용된다. 국제단위는 C/kg. ③ 선량당량(dose equivalent). 방사선방호를 위해 사용되는 양. 기호는 H. H는 방사선의 종류와 에너지에 의해 생체에 주는 효과를 보정하는 선질계수(Q)와 그 밖의 인자(예를 들면 선량률, 방사성동위원소에 의한 내부피폭시에는 그 핵종의 체내분포 등)에 근거한 보정계수(N)를 흡수선량(D)에 곱한 것, 즉 H=D-Q-N. 또한 D의 단위를 Gy 또는 rad로 표시하였을 때 H의 단위를 각각 시베르트(sievert, 기호 Sv) 및 렘(rem)이라고 한다. 따라서 1 Sv=102rem. 일반적으로 단위시간당의 선량을 선량률(dose rate)이라고 한다. |
||
| 영문 | dose | 한글 | 용량, 투여량, 방사선량 |
|---|---|---|---|
| 설명 | 1. 약제를 한 번 또는 하루에 사용하거나 복용하는 분량. 2. 물질이나 조직에 대한 방사선의 작용 정도를 나타내는 양. 즉, 방사선량이라는 개념은 어떤 한 점에 입사하는 방사선과 그 점 근처에 있는 물질에 대한 방사선의 물리적-화학적-생물학적 효과와의 관게를 정량적으로 나타내는 공통인 척도로서 생각된 것이다. 라드(rad)로 나타내는 흡수량, 렌트겐(R)으로 나타내는 조사 선량, 렘(rem)으로 나타내는 선량 당량으로 구분하여 쓴다. |
||
| 영문 | skin dose | 한글 | 피부선량 |
|---|---|---|---|
| 설명 | 1. 피부표면에서의 방사선의 공중선량으로 여기에는 1차방사선과 후방산란이 포함된다. 2. 피부에 흡수되는 선량. |
||
| ID | identification; iditol dehydrogenase; immunodeficiency; immunodiffusion; immunoglobulin deficiency; ... |
|---|---|
| TD | tabes dorsalis; tardive dyskinesia; T-cell dependent; temporary disability; terminal device; tetanus... |
| Lr | lawrencium; Limes reacting dose of diphtheria toxin |
| MRD | maximum rate of depolarization; measles-rindenpest-distemper [virus group]; medical records departme... |
| CD | cadaver donor; canine distemper; canine dose; carbohydrate dehydratase; carbon dioxide; cardiac dise... |
| TBARS | 2-thiobarbituric acid-reacting substance |
|---|---|
| CRD | Cross Reacting Determinant |
| CRM | Cross-reacting material |
| NCA | Non-specific cross-reacting antigen |
| SRS-A | Slow Reacting Substance of Anaphylaxis |
| minimal reacting dose | The minimal dose of a toxic substance causing a reaction, as manifested in the skin of a series of susceptible test animals; the assay is based on the development of a characteristic, minimal but definite, "standard," focal inflammation (congestion and oedema, induration, degenerative changes, and desquamation of epidermal cells). (05 Mar 2000) |
|---|---|
| cross-reacting agglutinin | An immune agglutinin specific for a group antigen. Synonym: cross-reacting agglutinin. (05 Mar 2000) |
| cross-reacting antibody | <immunology> Antibody specific for group antigens, i.e., those with identical functional groups, antibody for antigens that have functional groups of closely similar, but not identical, chemical structure. (05 Mar 2000) |
| cross-reacting material | <haematology> A substance sufficiently different from a reference substance (R) to have a perceptibly different function from R but sufficiently similar to R that it reacts with anti-R antibodies; e.g., mutant factor VIII may be defective or even inert in coagulation and yet be immunologically identified as factor VIII. (05 Mar 2000) |
| slow-reacting factor of anaphylaxis | Slow-reacting substance of anaphylaxis (SRS-A), a leukotriene of low molecular weight which is released in anaphylactic shock and produces slower and more prolonged contraction of muscle than does histamine; it is active in the presence of antihistamines (but not epinephrine) and seems not to occur preformed in mast cells, but as a result of an antigen-antibody reaction on the granules. Compare: peptidyl leukotrienes. Synonym: slow-reacting factor of anaphylaxis. (05 Mar 2000) |
| slow-reacting substance | Slow-reacting substance of anaphylaxis (SRS-A), a leukotriene of low molecular weight which is released in anaphylactic shock and produces slower and more prolonged contraction of muscle than does histamine; it is active in the presence of antihistamines (but not epinephrine) and seems not to occur preformed in mast cells, but as a result of an antigen-antibody reaction on the granules. Compare: peptidyl leukotrienes. Synonym: slow-reacting factor of anaphylaxis. (05 Mar 2000) |
| slow reacting substance of anaphylaxis | <immunology> Potent bronchoconstrictor and inflammatory agent released by mast cells, an important mediator of allergic bronchial asthma. A mixture of three leukotrienes (LTC4 mainly, LTD4 and LTE4) (18 Nov 1997) |
| direct reacting bilirubin | The fraction of serum bilirubin which has been conjugated with glucuronic acid in the liver cell to form bilirubin diglucuronide; so called because it reacts directly with the Ehrlich diazo reagent; increased levels are found in hepatobiliary diseases, especially of the obstructive variety. Synonym: conjugated bilirubin. (05 Mar 2000) |
| indirect reacting bilirubin | The fraction of serum bilirubin which has not been conjugated with glucuronic acid in the liver cell; so called because it reacts with the Ehrlich diazo reagent only when alcohol is added; increased levels are found in hepatic disease and haemolytic conditions. Synonym: unconjugated bilirubin. (05 Mar 2000) |
| absorbed dose | The amount of energy absorbed per unit mass of irradiated material at the target site; in radiation therapy, the former unit for absorbed dose is the rad; the current (S.I.) unit is the gray. (05 Mar 2000) |
| air dose | The radiation dose, expressed in roentgens, delivered at a point in free air. Synonym: air dose. (05 Mar 2000) |
| bone marrow dose | The cumulative dose to the blood-forming organ from therapeutic or nuclear fallout irradiation; the presumed leukemogenic dose. (05 Mar 2000) |
| booster dose | A dose given at some time after an initial dose to enhance the effect, said usually of antigens for the production of antibodies. (05 Mar 2000) |
| breast dose in mammography | <radiology> 180 mrad / view -- mid-breast dose, guideline: less than 1 rad for 2-view exam (12 Dec 1998) |
| maintenance dose | In chemotherapy, systematic dosage at a level that maintains protection against exacerbation. (05 Mar 2000) |
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|